Abstract We consider licensing of a non-drastic innovation by licensor that interacts with potential licensee in Stackelberg duopoly, comparing per-unit and ad-valorem royalty two-part contracts showing why when each deal should be used. contribute three findings to the literature. First, is preferred plays as leader marketplace, but follower. Second, only innovations do not hurt consumers are ...

Conflict of interest: P.M.R. has served as a consultant to ISIS, Vascular Biogenics, Amgen, Pfizer, and Boston Heart, and is listed as a co-inventor on patents held by the Brigham and Women’s hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Seimens. Neither P.M.R. nor the Brigham and Women’s Hospital rec...

The proliferation of international jurisdictional conflicts and competing “anti-suit injunctions” in litigation over the licensing standards-essential patents has raised concerns among policy makers United States, Europe China. This article suggests that national courts temporarily “stand down” from assessing global “fair, reasonable nondiscriminatory” (FRAND) royalty rates while bodies develop...

This paper shows that subsidy can naturally emerge as part of the equilibrium strategy of an innovator of a cost-reducing innovation in a Cournot oligopoly when the innovator is endowed with combinations of upfront fee and royalty. It is further shown that there are robust regions where the social welfare is higher in subsidy-based licensing compared to the regime where licensing involving subs...

We acknowledge that past researches discuss the strategy of the technology licensing by patentees all assume that technology innovation is exogenous. In this paper, we study on the patentee’s research and development (R&D) and licensing if the patentee is not in production. It is found that under different strategy, the level of R&D is different. And the fixed fee royalty is still the best lice...

Caring for very important persons (VIPs), including celebrities and royalty, presents medical, organizational, and administrative challenges, often referred to collectively as the "VIP syndrome." The situation often pressures the health care team to bend the rules by which they usually practice medicine. Caring for VIP patients requires innovative solutions so that their VIP status does not adv...

☆ This research was supported by a National Science Fellowship and the Ford Foundation Predoctoral Fellow from the National Science Foundation (BCS-0749 Washington Royalty Research Fund to Cheryl R. Kaise Fellowship to Heather Rieck. We thank the resea Identification Laboratory for their assistance with da members of the Kaiser/Cheryan lab, Sapna Cheryan an thoughtful feedback on drafts of this...

* Senior Staff, Advanced Propulsion Technology Group, 4800 Oak Grove Drive, M/S 125-109, Member AIAA. Copyright © 2005 by the American Institute of Aeronautics and Astronautics, Inc. The U.S. Government has a royalty-free license to exercise all rights under the copyright claimed herein for Governmental purposes. All other rights are reserved by the copyright owner. The Nuclear-Electric Pulsed ...

OnFebruary 27, 2011, Hollywood’s royalty will gather in Kodak Theater to honor the best films of 2010. To add a scientific twist on this year’s Academy Awards, Cell Culture dives beneath the skin of the top films’ protagonists, identifying a brain structure that impacts our ‘‘friend count,’’ genes that make a king stammer, a cellular fragmentation process that saves a solo hiker, and stem cells...